Hans Hammers, MD, PhD, and Moshe Ornstein, MD, MA, discuss data updates in advanced renal cell carcinoma (RCC) that were presented at the recent 2022 International Kidney Cancer Symposium.
EP. 1: Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)December 15th 2022
Hans Hammers, MD, PhD, describes how patients with advanced renal cell carcinoma are risk-stratified, and the go-to treatment approach for intermediate risk patients.
EP. 3: Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCCDecember 22nd 2022
Drs Hans Hammers reviews updated efficacy data on the use of lenvatinib plus pembrolizumab for frontline advanced renal cell carcinoma treatment.
EP. 5: Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 TrialJanuary 9th 2023
Dr Moshe Orenstein reviews the 5-year data update of the CheckMate 214 trial in favorable risk subgroups of advanced renal cell carcinoma.
EP. 6: Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC TreatmentJanuary 9th 2023
Drs Hammers and Orenstein describe how they manage the side effects of IO/IO combination treatments in their patients with advanced renal cell carcinoma.